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Background: Malnutrition is associated with an increased risk of cardiovascular death and may cause protein-energy
wasting in individuals with chronic kidney disease. A previous study demonstrated that blood cadmium levels (BCLs)
were associated with malnutrition in maintenance hemodialysis (MHD) patients. However, the correlation between
cadmium exposure and malnutrition remains unclear in chronic peritoneal dialysis (CPD) patients. This study examined
the possible adverse effects of environmental cadmium exposure in CPD patients.
Methods: A total of 301 CPD patients were enrolled and divided into 3 study groups based on the following BCL
tertiles: low (<0.19 μg/L), middle (0.19–0.39 μg/L), and high (>0.39 μg/L). Demographic, hematological, biochemical, and
dialysis-related data were obtained for analysis. The analysis also included values of nutritional and inflammatory markers.
Results: The BCLs of CPD patients were lower than those of MHD patients. At baseline, patients in the high BCL group
were older and had a higher prevalence of diabetes mellitus but lower serum albumin, creatinine, and phosphate levels
than the patients in the other 2 groups. After adjusting for potential variables, stepwise backward multiple linear
regression analysis revealed that age and alanine aminotransferase levels were positively associated with logarithmic
transformation of BCLs (log BCLs), while serum albumin levels were negatively associated with log BCLs in CPD patients.
The log BCLs were a significant determinant (beta coefficient ± standard error = −0.185 ± 0.074; P = 0.013) of nutritional
status and significantly associated with the presence of malnutrition (odds ratio = 2.64; 95% confidence interval: 1.07–6.48;
P = 0.035) in CPD patients after adjustment for related variables.
Conclusions: BCL is significantly associated with nutritional status and malnutrition in CPD patients. Therefore, it is
important for CPD patients to avoid environmental exposure to cadmium such as through smoking and consumption of
cadmium-rich foods.
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Cadmium is widely known as a toxic metal [1-3]. Environ-
mental and occupational exposure to cadmium is associ-
ated with several diseases, including renal dysfunction [2],
bone disease [2] and cancers [3]. Occupational studies have
shown that cadmium exposure is associated with increased
all-cause and cancer-related mortality [2]. Population-based
studies conducted in heavily polluted areas have also* Correspondence: tzunghaiyen@ntu.edu.tw
1Department of Nephrology and Division of Clinical Toxicology, Chang Gung
Memorial Hospital, 199, Tung-Hwa North Road, Taipei, Taiwan
2Department of Nephrology and Division of Clinical Toxicology, Lin-Kou
Medical Center, Taoyuan, Taiwan
Full list of author information is available at the end of the article
© 2014 Hsu et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orlinked cadmium exposure to an increased risk of cancer-
related, cardiovascular-related, and all-cause mortality [4,5].
Recently, the US national survey demonstrated a direct
correlation between environmental cadmium exposure
and all-cause, cancer, and cardiovascular disease mor-
tality among adults [6].
Cadmium has been shown to accumulate in the bones
of patients with end-stage renal disease (ESRD), and
increased blood cadmium levels (BCLs) have been ob-
served in maintenance hemodialysis (MHD) patients [7-9].
Additionally, our recent cross-sectional study demonstrated
that BCLs are associated with malnutrition and inflamma-
tion in MHD patients [10]. Furthermore, an 18-month
longitudinal study [11] demonstrated that BCLs are. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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However, the clinical significance of BCLs in chronic peri-
toneal dialysis (CPD) patients remains unknown, and the
possible adverse effects of environmental cadmium ex-
posure in CPD patients were not identified.
Recent evidence from clinical studies [12-15] indicated
that protein-energy wasting and residual renal function
are associated with short-term mortality in ESRD patients.
Correcting these risk factors offers a potential means for
reducing the mortality rates of CPD patients [15,16].
Therefore, it is important to identify correctable factors
associated with residual renal function, inflammation, and/
or malnutrition for the welfare of these patients. However,
the correlations between BCLs and residual renal func-
tion, inflammation, and malnutrition in CPD patients
remain unclear.
Therefore, we conducted a cross-sectional study to
evaluate the relationship between BCLs and health status
by performing clinical examinations of CPD patients.
Methods
Ethics statement
This clinical study was conducted in accordance with the
Declaration of Helsinki and was approved by the Medical
Ethics Committee of Chang Gung Memorial Hospital
(CGMH), a tertiary referral medical center in Taiwan.
All patients provided written informed consent for the
collection of data and subsequent analysis and the ap-
proval from Institutional Review Board was obtained.
All individual information was securely protected (by
delinking identifying information from main data set)
and available to investigators only. Furthermore, all the
data were analyzed anonymously.
Patients
All study participants were recruited from the Peritoneal
Dialysis Center of Lin-Kou Medical Center, CGMH. Only
patients undergoing CPD for more than 6 months were
enrolled. Subjects with a history of occupational exposure
to heavy metals or metal intoxication were excluded, as
well as those living in metal-contaminated areas or near
the cadmium-using factories, those with malignancies,
and those under 18 years of age. A total of 301 patients
were included. The CPD prescription for each patient
was based on the peritoneal membrane characteristics,
which were determined by peritoneal equilibration tests.
Intermittent therapies were used primarily for patients
with high transport characteristics, and continuous ther-
apies were used for those with average or low transport
characteristics. Of these patients, 51 were treated with
automated PD and 250 underwent continuous ambula-
tory PD, including 1 patient with 3 exchanges per
day, 164 patients with 4 exchanges per day (57 with
1.5 L/exchange, 101 with 2 L/exchange, and 6 with2.5 L/exchange), 22 patients with five 1.5-L exchanges,
and 63 patients with five 2-L exchanges per day. Low-
calcium (1.5 or 1.25 mmol/L) or standard-calcium dialysate
containing glucose (Na+, 135 mmol/L; lactate, 35 mmol/L;
Ca2+, 1.75 mmol/L) and icodextrin-based (7.5 g/dL) dialys-
ate were prescribed for each patient according to the peri-
toneal transport characteristics and serum calcium levels
required to maintain adequate ultrafiltration and normal
calcium levels. The dialysis prescription was aimed at
obtaining a total Kt/V of at least 1.8 per week.
The presence of primary renal disease and comorbid
conditions was determined after an in-depth review of
the medical records, including the history and physical
examination, progress notes, discharge summaries, con-
sultations, and biopsy results. Patients with diabetes mel-
litus (DM) were defined as those with a history of diabetes
diagnosed by a physician or any 2 subsequent fasting
glucose levels greater than 126 mg/dL. The presence of
cardiovascular disease (CVD), including cerebrovascular
disease, coronary artery disease, congestive heart failure,
and peripheral vascular disease, was recorded. History
of smoking, alcohol consumption, and drug use were
also recorded.
In order to assess the BCLs of the general population
in Taiwan, we also enrolled 63 healthy volunteers who
had normal renal function and no history of heavy metal
contamination or intoxication.
Measurement of BCLs
To ensure that the blood samples of the CPD patients
were not contaminated with cadmium during tests, the
samples were collected in cadmium-free plastic tubes.
At least two blood samples were obtained from each
patient before and 4 h after peritoneal dialysis. BCLs
were measured using a previously described method [17].
Briefly, 900 μL of a modifier solution of NH4H2PO4 +
HNO3 + Triton X-100 in deionized water and 100 μL of
whole blood or 100 μL of modifier solution and 900 μL
dialysate were added to a 1.5-mL Eppendorf tube and
immediately shaken. After overnight storage in a re-
frigerator, the tubes were warmed to room temperature
and then whirl-mixed for 5–10 s. The diluted blood
sample was transferred to graphite furnace sampler cups.
The cadmium levels of the acid-digested samples were
measured by electrothermal atomic absorption spectrom-
etry (SpectrAA-200Z; Varian, Palo Alto, CA, USA) with
Zeeman’s background correction and an L’vov platform.
Both internal and external quality control procedures were
used. A certified commercially prepared product (Seronorm
Trace Elements; Sero AS, Billingstads, Norway) was
used to determine the intra-batch accuracy and ensure
inter-batch standardization. The coefficient of variation
for the cadmium measurements was ≤5.0%. External
quality control was maintained via participation in the
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According to the following BCL value tertiles, all enrolled
patients were divided into 3 groups for statistical analysis:
low (1st tertile) BCL (<0.19 μg/L), middle (2nd tertile) BCL
(0.19–0.39 μg/L), and high (3rd tertile) BCL (>0.39 μg/L).
Laboratory, nutritional, and inflammatory parameters
All laboratory values, including blood cell counts, bio-
chemical data, normalized protein nitrogen appearance
(nPNA), peritoneal transport characteristics, residual renal
creatinine clearance (Ccr), peritoneal Ccr, standard total
weekly Ccr (normalized to body surface area), residual
renal Kt/V urea, peritoneal Kt/V urea, and total Kt/V urea,
were measured by automated and standardized methods.
All blood samples were collected in the morning after
at least 12 h of fasting. Serum albumin, creatinine,
cholesterol, triglyceride, hemoglobin, serum ferritin, and
transferrin saturation levels were assayed and recorded.
Serum calcium levels were corrected for serum albumin
levels using the following formula: Corrected calcium (mg/
dL) = serum calcium (mg/dL) + 0.8 × [4.0 − serum albumin
(g/dL)]. Serum albumin levels were used as a marker of
nutrition status. Serum ferritin and high-sensitivity C-
reactive protein (Hs-CRP) levels were used as markers
of inflammation. Serum Hs-CRP concentrations were
measured via immunonephelometry (Nanopia CRP;
Daiichi, Inc., Tokyo, Japan), with the lowest detection
limit of <0.15 mg/L. All other markers were measured
using an automatic analyzer according to standard la-
boratory methods.
Definition of malnutrition and inflammation
This study defined malnutrition as serum albumin levels
of <3.6 g/dL (<36 g/L), consistent with previous litera-
ture [10,13]. Since the lack of any definite Hs-CRP cutoff
level indicated an inflammatory state in CPD patients,
the presence of inflammation was defined as an Hs-CRP
level of >3 mg/L, which correlates with increased cardio-
vascular risk in the general population [18].
Statistical analysis
Unless otherwise stated, continuous variables are expressed
as the mean ± standard deviation (SD), and categorical
variables are expressed as the number or percentage for
each item. Comparisons between the 3 study groups were
analyzed via trend tests. Logarithmic conversion was per-
formed for non-normally distributed variables, including
BCLs (log BCLs), serum ferritin (log ferritin), Hs-CRP
(log Hs-CRP), residual renal Ccr (log renal Ccr), and intact
parathyroid hormone (iPTH) level (log iPTH).
To identify factors associated with log BCLs, we applied
a simple linear regression analysis for all variables. All
potential variables (P < 0.05) assessed with simple linearregression were entered into multiple linear regression
models with backward stepwise procedures. To evaluate
the variables related to malnutrition and inflammation,
we applied univariate and multivariate logistic regression
analysis to assess the odds ratio (OR) and 95% confidence
interval (CI) of these variables. All potential variables
(P < 0.05) assessed by univariate logistic regression ana-
lysis were entered into multivariate logistic regression
models with forward stepwise procedures. The level of
significance was set at P < 0.05. Data were analyzed using
the Statistical Package for the Social Sciences (SPSS) ver-
sion 12.0 for Windows 95 (SPSS Inc., Chicago, IL, USA).
Results
Study population characteristics
A total of 301 CPD patients (112 men and 189 women)
with a mean PD duration of 3.6 ± 2.9 years were enrolled
for analysis. The mean patient age was 49.5 ± 13.5 years
(range, 19–88 years). Based on the tertile of increased
BCLs, the subjects were stratified into 3 groups: the low
BCL (<0.19 μg/L) group, containing 101 subjects; the
middle BCL (0.19 − 0.39 μg/L) group, containing 102
subjects, and the high BCL (>0.39 μg/L) group, contain-
ing 98 subjects. Table 1 lists the demographic and clinical
characteristics, including age, gender, body mass index
(weight/height2), presence of DM and CVD, and the bio-
chemical and hematological data of the 3 groups. The
mean serum albumin and blood hemoglobin levels were
3.9 ± 0.5 g/dL (range, 1.1–5.0 g/dL) and 8.5 ± 1.4 g/dL
(range, 4.2–13.6 g/dL), respectively. The median serum
Hs-CRP level was 5.25 mg/L (range, 0.20–127.61 mg/L).
Compared with the patients in the low and middle BCL
groups, those in the high BCL group were older and
had a higher prevalence of DM but lower serum albu-
min, creatinine, and phosphate levels. No differences
existed between the 3 groups in terms of sex, body mass
index, smoking status, presence of hypertension, or his-
tory of CVD. The PD duration and peritoneal membrane
solute transport type were also not different. Furthermore,
the 3 groups did not differ in terms of erythropoietin
dose, total Kt/V, residual renal weekly Ccr, standard
weekly total Ccr, nPNA, hemoglobin, alanine amino-
transferase (ALT), transferrin saturation, ferritin, serum
corrected-calcium, iPTH, cholesterol, triglyceride, and
Hs-CRP levels, as well as the presence of viral hepatitis
B antigen and viral hepatitis C antibody (data not shown).
Dialysate cadmium concentrations, peritoneal cadmium
clearance, and BCLs of healthy volunteers and CPD patients
The median cadmium level was 0.09 μg/L (range, 0.01–
0.19 μg/L) in all dialysate samples (n = 13), which was com-
patible with the American Association for Advancement of
Medical Instrumentation Standards (cadmium: <10 μg/L).
After a 4-h abdominal retention in the 13 CPD patients,
Table 1 Baseline characteristics according to blood cadmium level tertile in CPD patients (n = 301)
Characteristics Low BCL group
(<0.19 μg/L)
Middle BCL group




(n = 101) (n = 102) (n = 98)
Demographics
Age (years) 45.3 ± 13.1 50.1 ± 13.1 53.2 ± 13.3 <0.001
Female sex 58 (57.4) 66 (64.7) 65 (66.3) 0.192
Body mass index (kg/m2) 22.7 ± 3.6 22.7 ± 4.2 22.7 ± 3.6 0.799
Smoking (Yes) 23 (22.8) 26 (25.5) 19 (19.4) 0.567
Comorbidity
Diabetes mellitus (Yes) 7 (6.9) 13 (12.7) 17 (16.7) 0.023
Hypertension (Yes) 90 (89.1) 88(86.3) 84 (85.7) 0.468
Previous cardiovascular diseases (Yes) 14 (13.9) 13 (12.7) 11 (11.2) 0.183
Dialysis-Related Data
Peritoneal dialysis duration (years) 3.8 ± 2.9 3.4 ± 3.1 3.8 ± 2.9 0.609
High and high average Cr D/P, 4 h (Yes) 44 (43.6) 58(56.9) 49 (50.0) 0.658
Erythropoietin (U/kg/week) 45.9 ± 32.5 44.5 ± 31.5 45.6 ± 31.0 0.810
Total Kt/V 2.17 ± 0.33 2.18 ± 0.42 2.16 ± 0.37 0.478
Residual renal Ccr (L/week/1.73 m2)* 2.51 (0.0, 71.9) 2.84 (0.0, 68.1) 2.99 (0.0, 56.4) 0.452
Standard total Ccr (L/week/1.73 m2) 63.8 ± 14.5 61.9 ± 13.4 62.9 ± 14.1 0.365
nPNA (g/kg/day) 1.09 ± 0.28 1.07 ± 0.26 1.05 ± 0.26 0.303
Biochemical Data
Hemoglobin (g/dL) 8.44 ± 1.56 8.53 ± 1.36 8.66 ± 1.32 0.250
Albumin (g/dL) 3.96 ± 0.46 3.85 ± 0.45 3.78 ± 0.50 0.006
ALT (IU/L) 16.5 ± 16.2 19.0 ± 12.2 19.7 ± 16.0 0.131
Creatinine (mg/dL) 12.8 ± 3.0 12.2 ± 2.9 11.6 ± 3.1 0.005
Transferrin saturation (%) 27.8 ± 13.6 27.0 ± 14.2 28.2 ± 12.3 0.835
Ferritin (μg/L)* 207.0 (6.9, 1930.0) 170.0 (5.9, 1497.0) 196.0 (7.0, 1909.0) 0.950
Corrected calcium (mg/dL) 10.0 ± 0.9 10.1 ± 0.8 10.2 ± 1.0 0.081
Phosphate (mg/dL) 5.5 ± 1.5 5.1 ± 1.3 5.0 ± 1.3 0.010
Intact parathyroid hormone (pg/mL)* 107.0 (5.0,998.0) 83.2 (5.0, 647.0) 81.0 (5.0, 1187.0) 0.165
Hs-CRP (mg/L)* 7.09 (0.20,124.45) 3.89 (0.26, 127.61) 3.52 (0.20, 59.8) 0.863
Cardiovascular Risks
Total cholesterol (mg/dL) 200.4 ± 44.5 209.6 ± 51.1 208.3 ± 41.9 0.223
Triglyceride (mg/dL) 214.1 ± 158.3 200.3 ± 131.7 190.2 ± 130.5 0.233
Note: P < 0.05 represents significant trends between the groups. *Non-normally distributed data are presented as median (minimum, maximum). Patients with
hypertension were either taking antihypertensive drugs regularly or their blood pressure was >140/90 mmHg at least twice. Cardiovascular diseases included
cerebral vascular disease, coronary arterial disease, congestive heart failure, and peripheral vascular disease. ALT, alanine aminotransferase; BCL, blood cadmium
level; CPD, chronic peritoneal dialysis; Ccr, clearance of creatinine; Cr, creatinine; Cr D/P, dialysate-to-plasma ratio of creatinine; Hs-CRP, high-sensitivity C-reactive
protein; nPNA, normalized protein nitrogen appearance.
Hsu et al. BMC Nephrology 2014, 15:17 Page 4 of 9
http://www.biomedcentral.com/1471-2369/15/17the median cadmium level of the dialysates was 0.10 μg/L
(range, 0.03–0.27 μg/L). In all study subjects, the mean
BCL was 0.53 μg/L and the median BCL was 0.27 μg/L
(range, 0.02–9.98 μg/L). In healthy volunteers, the mean
BCL was 0.27 μg/L and the median BCL was 0.15 (range,
0.02–1.03)μg/L.
Determinants of BCLs in CPD patients
As shown in Table 2, simple linear regression analysis
revealed that log BCLs were positively associated withage, PD duration, DM, and ALT potentially, but nega-
tively associated with albumin, creatinine, and phosphate
levels potentially.
After adjusting for these potential variables, stepwise
backward multiple linear regression analysis revealed
that only age and ALT levels were positively and signifi-
cantly associated with log BCLs and only albumin levels
(beta coefficient ± standard error [SE] = −0.167 ± 0.034,
P = 0.002) were negatively and significantly associated
with log BCLs.
Table 2 Determinants of blood cadmium levels (log BCLs) in CPD patients (n = 301)
Simple linear regression Backward stepwise multiple regression analysis
Variables Coefficient ± SE P Beta Coefficient ± SE P
Age (years) 0.009 ± 0.002 <0.001 0.006 ± 0.002 0.001
Peritoneal dialysis duration (years) 0.017 ± 0.008 0.040
Diabetes mellitus (Yes = 1) 0.171 ± 0.077 0.028
Albumin (g/dL) −0.142 ± 0.053 0.008 −0.167 ± 0.034 0.002
ALT (IU/L) 0.004 ± 0.002 0.030 0.003 ± 0.002 0.046
Creatinine (mg/dL) −0.027 ± 0.008 0.001
Phosphate (mg/dL) −0.052 ± 0.019 0.006
ALT, alanine aminotransferase; CPD, chronic peritoneal dialysis; iPTH, intact parathyroid hormone; Log BCL, logarithmic transformation of the blood cadmium level;
SE, standard error.
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As shown in Table 3, simple linear regression analysis
revealed that serum albumin levels were positively associ-
ated with hemoglobin, cholesterol, triglyceride, creatinine,
and phosphate levels potentially, but negatively associated
with age, DM, high and high average dialysate-to-plasma
ratio of creatinine (Cr D/P) at 4 h, log BCLs, and log Hs-
CRP levels potentially.
After adjusting for these potential variables, stepwise
backward multiple linear regression analysis revealed
that only hemoglobin, cholesterol, triglyceride, and cre-
atinine levels were positively and significantly associated
with serum albumin levels and only high and high aver-
age Cr D/P at 4 h, log Hs-CRP, and log BCLs (beta coef-
ficient ± SE = −0.185 ± 0.074, P = 0.013) were negatively
and significantly associated with serum albumin levels.
Specifically, in logistic regression analysis, the log
BCLs (OR = 2.64, 95% CI: 1.07–6.48, P = 0.035) were sig-
nificantly associated with malnutrition (serum albumin
levels of <3.6 g/dL) in the forward stepwise multivariate
logistic regression analysis.Table 3 Determinants of serum albumin levels in CPD patient
Simple linear regression
Variables Coefficient ± SE
Age (years) −0.011 ± 0.002
Diabetes mellitus (Yes = 1) −0.302 ± 0.081
High and high average Cr D/P, 4 h (Yes = 1) −0.264 ± 0.053
Hemoglobin (g/dL) 0.046 ± 0.017
Cholesterol (mg/dL) 0.002 ± 0.001
Triglyceride (mg/dL) 0.001 ± 0.000
Creatinine (mg/dL) 0.055 ± 0.008
Phosphate (mg/dL) 0.097 ± 0.019
Log BCL (μg/L) −0.277 ± 0.059
Log Hs-CRP (mg/L) −0.113 ± 0.056
CPD, chronic peritoneal dialysis; Cr D/P, dialysate-to-plasma ratio of creatinine; Log
logarithmic transformation of the high-sensitivity C-reactive protein level.Determinants of log Hs-CRP levels in CPD patients
Simple linear regression analysis demonstrated that age,
standard total weekly Ccr, serum albumin, triglyceride,
creatinine, and transferrin saturation levels were poten-
tially associated with log Hs-CRP levels (P < 0.05). After
adjusting for these potential variables, backward stepwise
multiple linear regression analysis revealed that age (beta
coefficient ± SE = 0.010 ± 0.004, P = 0.005) and standard
total weekly Ccr (beta coefficient ± SE = 0.006 ± 0.003,
P = 0.050) were positively and significantly associated with
log Hs-CRP levels, but transferrin saturation levels (beta
coefficient ± SE = −0.009 ± 0.003, P = 0.005) were negatively
and significantly associated with log Hs-CRP levels.
Discussion
The analytical results presented in this study demon-
strated an association between BCLs and nutritional status
and malnutrition in CPD patients. Following adjustment
for potential variables, BCLs were negatively correlated with
serum albumin levels and malnutrition in these patients.
Overall, each 10-fold increase in BCL was associateds (n =301)
Backward stepwise multiple regression analysis
P Beta Coefficient ± SE P
<0.001
<0.001
<0.001 −0.202 ± 0.064 0.002
0.008 0.050 ± 0.021 0.020
0.001 0.002 ± 0.001 0.044
0.001 0.001 ± 0.000 0.001
<0.001 0.047 ± 0.012 <0.001
<0.001
<0.001 −0.185 ± 0.074 0.013
0.045 −0.095 ± 0.052 0.043
BCL, logarithmic transformation of the blood cadmium level; Log Hs-CRP,
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of CPD patients. Moreover, each 10-fold increase in BCL
was associated with a 2.64-fold increase in the probability
of malnutrition development (serum albumin levels <3.6
g/dL) in these subjects. Since all subjects with cadmium
poisoning, occupational exposure to cadmium, and living
in cadmium-contaminated areas or near the cadmium-
using factories were excluded, this study is the first to dem-
onstrate that environmental cadmium exposure is signifi-
cantly associated with nutritional status and malnutrition
in CPD patients.
Reviewing the published articles, there were similar
studies performed in MHD population. A recent study
in Japan [19] revealed that cadmium accumulation in hair
correlated with malnutrition in 60 MHD patients. Further-
more, our previous study [10] also presented that environ-
mental cadmium exposure is significantly associated with
malnutrition in 954 MHD patients. Since malnutrition
may cause protein-energy wasting and is associated with
increased risk of mortality in ESRD patients [14,15], it
seems reasonable to imply that environmental cadmium
exposure may influence the nutritional status and survival
of CPD patients. Therefore, regular BCL measurements
may be required to assess protein-energy wasting and mor-
tality in CPD patients. However, the definite underlying
pathogenesis requires further investigation.
This study also first demonstrated that CPD patients
with high BCLs were older and had lower serum albu-
min and creatinine levels than those with lower BCLs. In
addition to the negative association between log BCLs and
the nutritional marker of serum albumin levels, stepwise
backward multiple linear regression analysis revealed posi-
tive associations between log BCLs and age and ALT
levels in CPD patients. Regardless of the route of expos-
ure, cadmium is progressively retained in the organism
and accumulates throughout life. The cadmium body bur-
den, negligible at birth, increases continuously during the
lifespan until the approximate age of 60 to 70 years [4].
Hence, it seems reasonable to suggest that age is positively
associated with cadmium in CPD patients. Cadmium
accumulates in the liver and even more so in the kidneys,
which can contain up to 50% of the total cadmium body
burden in individuals with low levels of environmental ex-
posure [4]. There are reports indicating that cadmium-
induced toxicity results from the generation of free radi-
cals [20,21]. Additionally, an increase of free radical for-
mation may also be observed in patients with CPD [22].
Free radicals lead to lipid peroxidation, which might in-
duce organ damage and structural change [23]. More-
over, the liver is a critical target organ of acute or
chronic exposure to cadmium [24]. Hence, it seems
reasonable to consider that ALT levels may be posi-
tively associated with BCLs in CPD patients. Factors
that impact the liver function may result in the releaseof cadmium from the liver, which may increase the
BCL [17]. However, further study is needed to clarify
the mechanism.
Although the literature [25,26] indicates that low iron
body stores or calcium status may enhance cadmium
absorption and increase BCLs in mice and humans, the
current study demonstrated that patients in the high
BCL group did not exhibit significantly lower corrected
levels of calcium, ferritin, and transferrin saturation,
compared with those in the other 2 groups. Hence,
BCLs were not correlated with serum corrected calcium
and iron levels in the study subjects. These results may
be explained by the fact that dialysis patients regularly
receive iron supplements for anemia to maintain erythro-
poietin effects and obtain calcium from the calcium-
containing phosphate binders and dialysate. However,
further studies are needed to clarify these observations.
In general population, cigarette smoking is significantly
correlated with cadmium levels [2]. However, the high
BCL group did contain a significantly higher percentage
of smokers compared with those in the other 2 groups
in this study. Unlike the general population with normal
kidneys, accumulation of cadmium in CPD patients may
be caused by the nearly complete loss of renal function
in the ESRD population and the difficulty of cadmium
removal under current dialysis settings [7,9,27]. This
may be the reason for which the smoking status did not
differ significantly between the 3 study groups.
On reviewing the published articles, the different levels
of serum CRP between patients with CPD and those with
MHD are controversial. In this investigation, the median
Hs-CRP level (5.25 mg/L; range, 0.20–127.61 mg/L) of
CPD patients was higher than that (2.88 mg/L; range, 0.20–
73.21 mg/L) of MHD patients in our previous study [10].
This result was similar to a previous study [28], which
presented that the mean CRP level (12.8 ± 9.7 mg/dL)
was higher in CPD patients than that (8 ± 4.5 mg/dL)
in MHD patients. The reasons underlying the high
Hs-CRP levels of CPD patients may be that (1) the
inflammatory markers in these subjects can be en-
hanced both by the peritoneal irritation during PD and
the decreased removal of the cytokines due to reduced
residual renal function [29], and (2) some MHD pa-
tients (197/954 = 20.6%) received hemodiafiltration with
ultrapure dialysate, which may reduce the Hs-CRP ele-
vation in dialysis sessions [30]. However, other studies
demonstrated that patients with MHD had higher CRP
or Hs-CRP levels than patients with CPD [31,32]. Add-
itionally, other studies showed that the levels of CRP or
Hs-CRP were similar between patients with MHD and
those with CPD [33,34]. Therefore, further studies are
needed to clarify this issue.
In this investigation, the BCL was not associated with
inflammation in CPD patients. However, in our previous
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associated with inflammation in the dialysis population.
The reason for which BCL is associated with inflamma-
tion in MHD patients but not in CPD patients may be
the lower median BCL (0.27 μg/L; range, 0.02–9.98) of
CPD patients relative to that (0.39 μg/L; range, 0.02–
16.45, n = 954) of MHD patients. Moreover, only 9.4%
of non-smoking CPD patients had BCLs of >1 μg/L,
while 17.8% of non-smoking MHD patients had BCLs
of >1 μg/L, a level indicating abnormal concentrations
in humans as reported in a previous study [2]. Since PD
and HD cannot effectively remove cadmium from the
body, the reasons underlying why CPD patients have a
lower BCL than MHD patients remain unknown. There
are several potential explanations for this observation:
(1) the younger age (49.3 ± 13.5 years) of CPD patients
versus MHD patients (56.1 ± 13.5 years), suggesting lower
BCLs in CPD patients since BCL increases continuously
throughout life; (2) lower serum albumin levels in CPD
patients (3.9 ± 0.5 g/dL) than in MHD patients (4.1 ±
0.4 g/dL), which indicates a relatively poor intake in CPD
patients compared to MHD patients, suggesting lower
dietary cadmium ingestion in CPD patients; (3) HD dur-
ation of 6.7 ± 0.2 years versus PD duration of 3.6 ± 2.9 years,
as a longer duration of dialysis may cause increased
cadmium accumulation in the body; (4) the residual
daily urine amount ≧ 100 mL is 63% (190/301) in CPD
patients versus 20.9% (199/954) in MHD patients, indi-
cating elevated cadmium excretion in the urine of CPD
patients; and (5) the hemoglobin level (8.5 ± 1.4 g/dL)
in CPD patients is lower than that (10.9 ± 1.6 g/dL) of
MHD patients, and since most cadmium binds to
hemoglobin in red blood cells, CPD patients with lower
hemoglobin levels may have lower BCLs compared to
MHD patients. Moreover, since no similar reports in
CPD patients are noted, we only can compare the data
with those of the general population and MHD pa-
tients. The geometric mean BCL was 0.53 μg/L in our
study subjects, which is higher than that (0.44 μg/L)
of the general population in America [35] and (0.27 μg/
L) of the general population in the study area, but simi-
lar to that (0.51 μg/L) of the general population in
Europe [36]. Considering normal hemoglobin in the
general population, the BCL of CPD patients, similar to
the previous report in MHD patients [10], was higher
than those of general population. A previous report in-
dicated that the exposure to relatively low environ-
mental levels of cadmium appears to be a determining
factor in the development of ESRD [37]. Moreover, in
patients undergoing chronic dialysis, cadmium elimin-
ation is very difficult because of their very low residual
renal function and the inefficient cadmium removal by
the current dialysis settings. All these may be contribut-
ing factors to the higher BCL found in patients withCPD compared to the general population in the study
area. However, further study is needed to clarify these
observations.
Cadmium is a ubiquitous environmental pollutant in
industrialized countries [4]. The cadmium levels of in
air due to contaminated fumes or dust vary greatly between
different industries, such as smelters, pigment plants, and
battery factories [2]. Compared with the general popula-
tion, workers in the non-ferrous industries are exposed to
higher levels of cadmium, mainly through inhalation of
contaminated substances with other toxins [4]. Moreover,
the application of phosphate fertilizers may lead to the
contamination of soils and then increase the absorption
of cadmium by crops and vegetables, grown for human
consumption [2].
Diet is the main source of environmental cadmium
exposure in the non-smoking population in most coun-
tries [38]. Cadmium is present in all foods virtually in
varied concentrations, depending on the kind of food and
the cadmium levels in the environment. High cadmium
concentrations are observed in mollusks and crustaceans
such as oysters and other bivalve mollusks, cephalopods,
and crabs [38]. High cadmium levels are also present
in offal products of visceral organs, especially from livers
and kidneys of older animals, as well as in oil seeds, cocoa
beans, and certain mushrooms [4,38]. Plant products
generally contain higher cadmium levels than animal
products like meat, egg, milk, and fish [38]. Moreover,
among vegetables, green leafy vegetables, cereals, pota-
toes, and roots, such as carrots, contain higher cad-
mium concentrations than other vegetables [38]. Tobacco
smoking is another important source of cadmium expos-
ure. One cigarette may contain approximately 1–2 μg of
cadmium [38]. The results of the current study indicate
that avoiding the intake of cadmium-rich foods and to-
bacco smoking is critical for the survival of long-term dia-
lysis patients. Additionally, the mean BCL of 63 healthy
volunteers in our study area was 0.27 μg/L, which was
lower than the mean BCLs in the general population of
America (0.44 μg/L) and Europe (0.51 μg/L). The rea-
son for the lower mean BCL found in the study area
compared to that found in America and Europe is un-
certain. However, the industrial emissions, the applica-
tion of fertilizer, sewage sludge, cigarette smoking, and
dietary habits may influence the mean BCL of the study
population. Further study is needed to clarify this
observation.
In ESRD patients, there are many causes of osteomalacia,
including vitamin D deficiency, acidosis, uremic toxins, and
aluminum accumulation in bone [39]. However, the serum
concentrations of iPTH may be at any level and only bone
histology can establish the diagnosis of osteomalacia sec-
ondary to dialysis with certainty [40]. Additionally, iPTH
levels may be clinically influenced by several other factors,
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calcium-containing dialysates, and supplementation of vita-
min D3. For these reasons, although cadmium may induce
osteomalacia in a clinical setting, a relationship between
cadmium and iPTH levels could not be observed in this
study. However, further study is needed to clarify the
underlying mechanism.
Cadmium is a cumulative toxic metal with a long elim-
ination half-life [10]. In acute exposure, inhalation of
cadmium oxide fumes may induce inhalation fever or
chemical pneumonitis [41]. In chronic exposure, cad-
mium poisoning may cause renal tubulopathy, induce
osteomalacia, and diffuse osteoporosis [41]. Furthermore,
the International Agency for Research on Cancer (IARC)
has classified cadmium as a carcinogen in humans [41].
Due to the cross-section nature of this study, the causal
relationship between BCLs and malnutrition was not iden-
tified. Further investigation is required to clarify whether
cessation of possible environmental exposure, including
smoking and ingestion of cadmium-rich foods, may im-
prove the nutritional status and reduce the malnutrition
rate of CPD patients. Moreover, the small number of pa-
tients in each group, the higher mean age, and absence of
an adequate control group are also limitations of this
study. Based on the results of previous studies [4,38,42],
blood cadmium has a very long half-life (approximately
7–16 years) in humans [42] and BCLs are well corre-
lated with urinary cadmium levels [4,38]. Therefore, BCLs
and urinary cadmium levels may reflect the total cadmium
burden. The long half-life of cadmium is due to the influ-
ence of cadmium body accumulation on the BCL. Thus,
after long-term low-level exposure, BCL measurement of-
fers a useful means to estimate the total body burden of
cadmium, as it is closely related to the total body burden
of cadmium in the general population [4,35,38]. Since
CPD patients with high-level cadmium exposure were ex-
cluded from the current study, the BCLs of the patients in
our study, who only had long-term low-level cadmium ex-
posure, may represent their total body cadmium burden.
Therefore, BCL was a good index of the total body burden
of cadmium in the CPD patients in this study. Hence, the
results of our study indicate that chronic environmental
low-level cadmium exposure may play a role in the in-
creased malnutrition of CPD patients.
Conclusions
This is the first study to demonstrate that BCLs are
related to age, serum albumin levels, and ALT levels in
CPD patients. Moreover, BCLs were negatively associated
with nutritional status and related to high probability of
malnutrition development in CPD patients. Additionally,
the World Health Organization has classified cadmium as
a human carcinogen [2], and cancer is a common cause
of mortality in ESRD population [43]. These resultsindicate that reducing environmental cadmium expos-
ure, particularly by avoiding smoking and the intake of
cadmium-rich foods, may be critical for the improve-
ment of nutritional status and survival of these patients.
However, further investigations are needed to clarify
and confirm these observations.
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